Podcasts about blue rock

In this episode of The Top Line, Fierce Biotech’s Chris Hayden sat down with Dr. Juergen Eckhardt of Bayer and Dr. Seth Ettenberg of BlueRock Therapeutics to discuss an innovative partnership that’s reshaping how big pharma teams up with biotech startups. BlueRock, a wholly owned subsidiary of Bayer, operates with the independence of a small biotech while benefiting from Bayer’s global reach and infrastructure. The “arm’s-length” model gives BlueRock the agility to innovate while leveraging Bayer’s resources in manufacturing, clinical trials and commercialization. The collaboration has already led to major milestones, including the development of a promising cell therapy for Parkinson’s disease, which is expected to enter Phase 3 trials later this year. “This isn’t just a partnership—it’s a relationship,” Eckhardt said. “We’re combining the best of both worlds: biotech speed and pharma scale.” The episode also explores how Bayer’s experience in biologics manufacturing has helped BlueRock overcome one of regenerative medicine’s biggest challenges—scaling complex cell therapies. The model has proven so effective that Bayer has since replicated it with other companies, signaling a broader shift in how the company approaches innovation. To learn more about this unique partnership and what it means for the future of neurological disease treatment, listen to the full episode of The Top Line.See omnystudio.com/listener for privacy information.

Join us on the MuppeTrek Podcast! On Fraggle Rock, both the Fraggles and Sprocket must face their fears in "The Beast of Bluerock." And Star Trek TNG episode, "Samaritan Snare." The Pakleds just really want to make things go. Can you blame them?!

Join us on the MuppeTrek Podcast! On Fraggle Rock, both the Fraggles and Sprocket must face their fears in "The Beast of Bluerock." And Star Trek TNG episode, "Samaritan Snare." The Pakleds just really want to make things go. Can you blame them?!

In this episode, Annie Warmke - President of Blue Rock Station LLC and Warmke Farm LLC provides a highly detailed story of the work of the organization including the history, mission, creation of the food forest, goals, future strategic plans and more.

On this co-hosted episode of UTH, Lee-Ann and Imogen are joined by Ani Tuna, head of tax advisory at BlueRock. Ani delves into her passion for tax, specifically in the small business CGT concession space, and why they are a crucial tool for the SME community. Tune in to this episode to hear more about: The definition of a small business CGT concession and why they're important. Why Ani views small business CGT concessions as her “first love”. Common and recurring errors she sees when applying the concessions. Missed opportunities. What clients need to know and what they should ask. We want to hear from you! Contact Imogen Wilson at imogen.wilson@momentummedia.com.au or Lee-Ann Hayes at lhayes@accurium.com.au if you believe there is a topic that needs to be delved into further.

‘Thy words were found, and I did eat them; and thy word was unto me the joy and rejoicing of mine heart:  for I am called by thy name, O Lᴏʀᴅ God of hosts.'—Jeremiah 15:16

This week, Rocksy is joined by Leigh Fernando and Daniel Zaffino from BlueRock. They discuss how BlueRock has grown from an accounting practice to a 300-person organisation with multiple divisions, focusing on holistic client service, organic talent development, and a culture of collaboration and continuous improvement. Leigh Fernando LinkedIn: https://www.linkedin.com/in/leighfernando/ Daniel Zaffino LinkedIn: https://www.linkedin.com/in/daniel-zaffino/ BlueRock Website: https://www.bluerock.com.au/ Life at BlueRock Video: https://vimeo.com/1073057694/28f170c7c1 Visit The Adviser Portal and partner with Zurich and OnePath today: https://ensombl.com/go/20250408 Recognise real-world learning as CPD: https://ensombl.com/cpd/ General Disclaimer – https://www.ensombl.com/disclaimer/

In this episode Som Seif, CEO of Purpose Investments, joins us to challenge common misconceptions about private markets. First, we discuss the current state of markets. Seif explains why private assets—private equity, private credit, and private real estate—are becoming essential components of modern investment portfolios. He discusses how institutional-grade private investments have become accessible to retail investors, debunks myths about risk and illiquidity, and outlines how these assets can enhance diversification, generate uncorrelated returns, and offer a more stable investment experience. Finally, we delve into how private sub-advisor managers like Apollo, Pantheon, and BlueRock are taking a significant role in democratizing access to these private market opportunities. 01:22 – Introduction: Debunking Private Markets 01:39 – Opening Disclaimer 01:58 – The State of Markets in 2025: Uncertainty & Opportunity 04:50 – Emotions vs. Rational Investing: Avoiding Reactionary Mistakes 09:17 – Why Private Markets Matter Now More Than Ever 10:04 – The Rise of Private Investments for Retail Investors 14:56 – Breaking the Myth: Institutional vs. Retail Access 16:58 – How Private Market Investments Are Being Democratized 21:03 – The Role of Private Assets in Portfolio Construction 23:34 – Private Equity: The Strategic Edge Beyond Public Markets 29:26 – Private Credit: A Rising Opportunity Amid Bank Retrenchment 33:55 – The Convergence of Private Equity & Private Credit 37:41 – Addressing Liquidity Concerns in Private Market Investing 45:27 – Purpose Investments' Approach to Private Market Accessibility 47:48 – What Advisors Need to Know About Private Markets 49:79 – Final Takeaways: A Call to Reevaluate Private Investments #PrivateMarkets #AlternativeInvestments #PrivateEquity #PrivateCredit #RealEstate #PortfolioManagement #WealthManagement #InstitutionalInvesting #InvestmentStrategy #FinancialMarkets

Join us for an insightful episode as we sit down with Mark Tomishima, Senior Vice President at BlueRock Therapeutics, to explore the latest advancements in regenerative medicine. Mark shares his experiences leading genome engineering and stem cell research, discusses key challenges in cell therapy development, and offers valuable career advice for aspiring scientists. Don't miss this deep dive into the cutting-edge work being done at BlueRock Therapeutics to revolutionize the future of medicine! Hosted by Sophia Deng.

Show #1088 Jelly 01. Sam Joyner - Must Be Jelly (3:42) (When U Need A Friend, self-release, 2020) 02. Andy Cohen - I Ain't Gonna Give You None Of My Jelly Roll (2:42) (Tryin' To Get Home, Earwig Records, 2020) 03. William Clarke - Must Be Jelly (7:03) (Blowin' Like Hell, Alligator Records, 1990) 04. Taj Mahal - I Ain't Gonna Let Nobody Steal My Jellyroll (3:14) (The Natch'l Blues, Columbia Records, 1968) 05. Screamin' John & Td Lind - Jelly Roll (3:20) (Mr. Little Big Man, Down In The Alley Records, 2019) 06. The Ford Blues Band - Jelly Jam (3:43) (Another Fine Day, Blue Rock'it Records, 2003) 07. Philip Kroonenberg - Jelly (4:03) (Grounded, Munich Records, 1998) 08. Delta Moon - Jelly Roll (2:59) (Low Down, Jumping Jack Records, 2015) 09. Joe Bonamassa - Jelly Roll (2:12) (Sloe Gin, J&R Adventures, 2007) 10. Roland - Mr. Jelly Roll Baker (4:30) (Little Sweet Taste, Play That Beat!, 1994) 11. Leon Redbone - Mr. Jelly Roll Baker (3:45) (Double Time, Warner Bros Records, 1977) 12. Lonnie Johnson - He's A Jelly Roll Baker (2:45) (78 RPM Shellac, King Records, 1951) 13. Lonnie Johnson - He's A Jelly Roll Baker (3:15) (78 RPM Shellac, Bluebird Records, 1942) 14. Whistling Rufus - (Who's Gonna Do Your) Sweet Jelly Rollin' [1933] (3:30) (Rude Dudes, Document Records, 2003) 15. Jimmie Gordon - Sweet Jelly Rollin' [1936] (2:46) (1934-1938 The Remaining Titles, Old Tramp Records, 1993) 16. Parlor Greens - The Jelly Roll (2:36) (In Green We Dream, Colemine Records, 2024) 17. Merle Travis - Jelly Roll Blues (2:38) (Rough Rowdy & Blue, CMH Records, 1986) 18. Doc Pomus - Jelly Jelly (3:05) (Blues in the Red, Rev-Ola Records, 2006) 19. Anthony Geraci - Jelly Jelly (6:27) (Daydreams In Blue, Shining Stone Records, 2020) 20. Big Max - Jelly Jelly (5:29) (Big Max, self-release, 2005) 21. R.J. Mischo - Selling the Jelly (5:37) (West Wind Blowin, CrossCut Records, 1999) 22. Guy Davis - Jelly Bone Jelly (3:17) (Call Down The Thunder, Red House Records, 1996) 23. Kerry Kearney Band - Shakin' Like Jelly (2:49) (Smokehouse Serenade, Highlander Records, 2019) 24. John Ginty - No Jelly (6:18) (No Filter, American Showplace Music, 2015) Bandana Blues is and will always be a labor of love. Please help Spinner deal with the costs of hosting & bandwidth. Visit www.bandanablues.com and hit the tipjar. Any amount is much appreciated, no matter how small. Thank you.

Send us a textMatt Defirdinando is an external wholesaler in the Pacific Northwest. 3 times in his career he's taken his sales territory from the bottom of the trade run to the top. He discusses a few ways he's done that, specifically: mistakes to avoid, leverage to get in front of more advisors, and some fun stories/examples along the way.Check out his series "10x Wholesaling Blueprint" to skyrocket sales & commissions while avoiding burnout. This information is educational in nature and does not constitute a financial promotion, investment advice or an inducement or incitement to participate in any product, offering or investment.  The opinions expressed are solely those of the speakers and do not reflect the opinions of Bluerock Capital Markets, LLC or its affiliates. Bluerock is not adopting, making a recommendation for or endorsing any investment strategy or particular security. All investing is subject to risk, including the possible loss of principal.

Personal insurances often something put in the 'too hard' basket, but to kick of the new year- good time to reflect and review. In this episode with Bluerock insurance advisor Jason Hugo, we explore: • when should you consider getting insurance (tip: easier to get when younger/healthier) •differences with income protection, TPD, trauma insurances • level vs stepped premiums, breakeven points •insurance changes since October 2021 •agreed value vs indemnity value •cancer diagnoses being common event for claims •case studies •is there such a thing as over-insurance?Music Credit: Bass Nation.Send in your questions to: passiveincomedoctors[AT]gmail.com

We love to hear from our listeners. Send us a message.On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rhakit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments. They cover the limitations of current PD medications, how cell therapies might offer a different approach to long-term symptom management, and how BlueRock is doing traditional dopamine replacement therapy differently.Subscribe to the podcast!Apple | Spotify | YouTube

Hot topic is SMSF (Self Managed Super Fund)•what minimum balance to start SMSF•what assets do doctor clients invest inside SMSF•property and SMSF, how can be powerful tool to growth retirement savings•case study- commercial property. growing from 1 to 6 million!Disclaimer- as always, speak to your own licensed advisorMusic Credit: Bass Nation.Send in your questions to: passiveincomedoctors[AT]gmail.com

The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.

Seven months after two teenagers are murdered outside Vallejo, California, the killer reemerges. He shoots two young people at a park on the outskirts of the city, but this time one of the victims survives. Shortly after the attack, the killer calls the Vallejo police department and sets in motion a pattern of communication that will be unrivaled in American criminal history. A month later, he sends letters to three newspapers and includes a cipher that contains a coded message.   Join Black Barrel+ for ad-free episodes and bingeable seasons: blackbarrel.supportingcast.fm/join   Apple users join Black Barrel+ for ad-free episodes, bingeable seasons and bonus episodes. Click the Black Barrel+ banner on Apple to get started with a 3-day free trial.   On YouTube, subscribe to INFAMOUS+ for ad-free episodes and bingeable seasons: hit “Join” on the Legends YouTube homepage.   For more details, please visit www.blackbarrelmedia.com. Our social media pages are: @blackbarrelmedia on Facebook and Instagram, and @bbarrelmedia on Twitter. Learn more about your ad choices. Visit megaphone.fm/adchoices

BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson's disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.Listen and subscribe so you never miss an episode!

Limited Government and Freedom Runs in Our Blood- In this episode co-hosts Wendy Patrick & Larry Dershem interview Miyu Oda-DesHotels about the work Turning Point USA is doing all across America to inform young people about our great national heritage, and the protections found in our Constitution & Bill of Rights that include freedom of speech, limited government, and our right to bear arms to stave off tyranny from without and from within.  Also, ... TikTok -- Fact vs. Fiction- In our second segment, we interview Jason Sheppard, founder of Wimkin Social Media (now approaching 10 million users), about the new TikTok bill in Congress.  Is the TikTok just a harmless app used by more than 170 million Americans and 7 million small- and mid-sized U.S. businesses, or is it a spy tool employed by Communist China to actively gather information on young Americans to influence, infiltrate, and undermine the United States?  Listen to what our expert thinks, then you decide.  See omnystudio.com/listener for privacy information.

Heather Smith and Tyler Caskey delve into the latest technology transformations and feature and functionality updates for the start of the year. In this episode, accounting apps specialist Heather Smith and Tyler Caskey, partners at TheBeanCounters, discuss recent developments in real-time banking transactions, direct digital receipting and multi-currency transactions. They also explore updates and new features in the reporting space across cash flow forecasting, automatic workflows, intercompany loan reconciliations and ESG. Heather and Tyler also chat about some of the big announcements in the accounting tech space including the launch of WorkflowMax by BlueRock and Xero ending classic invoicing later this year. 

Pierwsze pieniądze zarobił, gdy sprzedał wiaderko własnoręcznie zebranych wiśni i czereśni. Miał wtedy około 10 lat. Odkąd pamięta ciągnęło go do samodzielności i możliwości decydowania o sobie. 
 W dzisiejszym odcinku Maciej Panek opowiada o tym, jak wyglądała jego droga do miejsca, w którym jest dzisiaj. A jest to bardzo ciekawa opowieść! Każdy przystanek na jego prywatnej i zawodowej ścieżce zawsze przynosił jakąś wartość i inspirował do dalszego działania. Maciej ma dyplom elektromontera górnictwa podziemnego, uczył się w szkole oficerskiej, a nawet pracował jako strażnik miejski i prowadził sklep spożywczy. Potem zaczął inwestować na giełdzie, ale stracił wszystkie pieniądze… Przez 17 lat Maciej był właścicielem firmy, które nie była znana szerszemu odbiorcy, ponieważ działała głównie w modelu B2B. Ale carsharing zmienił dosłownie wszystko. Przed firmą PANEK wielkie cele - miliard złotych obrotu i ekspansja na światowe rynki. Z Maciejem rozmawiamy między innymi o tym: Jak umiejętnie przełożyć model biznesowy, który dobrze funkcjonuje za granicą, na polskie realia? Jak stworzyć dobry i współpracujący ze sobą zespół? Jak carsharing zmienił mobilność Polaków? Jak samochody autonomiczne wpłyną na przyszłość? Dlaczego warto stawiać sobie wielkie cele? Jak dbać o zdrowie i energię przedsiębiorcy na co dzień? Dlaczego warto realizować swoje marzenia dzisiaj, a nie jutro?

Arabian Business listed him in Top 100 Business people to know in Dubai in 2023. Sadi Abdel-Kariem is the current CCO of BlueRock TMS, an AI-powered logistics platform. He also served as former CEO of Slimstock (Africa, Turkey and Middle-East), a supply chain management software company.Sadi brings a wealth of knowledge and experience as an intrapreneur where he goes in to large multinationals to turn things around. Having worked in C-suite positions in banking, oil and gas and now heavily involved in the tech industry, this man specialises in going into businesses and turning things around for the better.In this conversation, Michael and Sadi discuss the future of tech, crypto and blockchain and the practical tools it takes to be able to create the life you want. Hosted on Acast. See acast.com/privacy for more information.

Aaron embarks on a time-travel journey to revisit a cherished moment from his youth.  Story created & performed by: Aaron Calafato Senior Audio Engineer: Ken Wendt  Additional vocals: Cori Birce  Art: Pete Whitehead  Original Music: thomas j. duke  • We want to hear from you! Drop us a line and tell us about your favorite episode or how it reminded you of a memory! https://www.7minutestoriespod.com/contact • Support 7MS by treating yourself to some merch! https://www.7minutestoriespod.com/merch • Book a 1 on 1 storytelling class with Aaron: https://www.aaroncalafato.com/1on1coaching • Want help developing, launching, or producing your podcast? Set up a call with Aaron and 7MS Audio Engineer Ken! https://www.valleyview.fm/contact

Doc has your grandma's crockery. Peak '80s Dad fashions. What is the Doozer Equinox? This trio of wemblers defends wembling! The introduction of Large Marvin! Limbo-ing hype rats, swimming Fraggles, and Extra Beings. Yeet the puppet (serious). How many times will Adam get fired before the end of the episode? With special guest Jarrod Fairclough.

Dr. Stefan Irion is the Chief Scientific Officer of BlueRock Therapeutics and Dr. Viviane Tabar is the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center.  In this special episode, recorded in front of a live audience in New York, they talk about their work on BlueRock's clinical trial for bemdaneprocel — a stem cell-derived investigational cell therapy for Parkinson's disease. They also discuss what's next for cell therapy and diversity in science and in patients.

For many individual investors, the traditional 60/40 portfolio focused on stocks and bonds was the only option they had for investment plans. Bluerock is among a group of alternative asset managers creating offerings meant to increase access to other asset types and investment structures.  In this episode, David Bodamer speaks with Ramin Kamfar, CEO of … Read More Read More

This week on Tapod we sit down with the brilliant Sabrina Del Borrello, Head of People of Culture at Bluerock focussing on headcount growth in a scale up. Bluerock has doubled their headcount over the past three years and looking to double again. We talk through growing pains like tech stack, AI, competing for talent, creating a talent community and building internal business cases.It's a fantastic reminder of how internal recruitment should be.Thanks so much to our brand new sponsor for November – RefApp.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bayer has recently opened a new plant in California to produce cell therapies, specifically a Parkinson's disease treatment being tested by its subsidiary Bluerock. This is a significant step forward in the field of cell therapy development.Meanwhile, Sana, another cell therapy developer, is implementing cost-saving measures, including layoffs and delaying certain research projects. These actions are aimed at ensuring the company's financial stability.In the world of biotech, Crispr gene editing technology is gaining increasing importance. Many companies in this field are led by former students of the pioneering scientists in the Crispr field. This shows the significant impact and potential of this technology.After a slow summer, there has been an uptick in biotech M&A activity. One notable acquisition is that of Orchard Therapeutics. This indicates the growing interest and investment in the biotech industry.In regulatory news, Pepgen has received clearance from the FDA to begin a study of its muscular dystrophy drug. This is an important milestone for the company, and we can expect to see the first results of this study next year.On the other hand, Alnylam has faced a setback as the FDA denied expanded approval for its RNA drug for a rare heart condition. This decision has set back the company's plans, highlighting the challenges faced by pharmaceutical companies in gaining regulatory approval for their products.Moving on to other news, Alvotech, a biopharmaceutical company, has received another rejection from the FDA for its biosimilar of Stelara. The FDA cited "deficiencies" at Alvotech's manufacturing plant as the reason for the rejection. This marks the fourth FDA rejection for Alvotech since last year.In a recent acquisition, Biogen has announced layoffs at Reata Pharmaceuticals, which it acquired for $7 billion. These layoffs will impact approximately one-third of Reata's workforce.In regulatory news, the European Commission has ordered Illumina to divest its subsidiary Grail. This decision comes after years of regulatory challenges and investigations.In clinical trial updates, Eli Lilly's mirikizumab has shown promising results in a Phase III trial for Crohn's disease. Over 54% of patients treated with mirikizumab achieved clinical remission at 52 weeks. Eli Lilly plans to submit a marketing application for mirikizumab in Crohn's disease to the FDA in 2024.Overall, these developments highlight the challenges faced by pharmaceutical companies in gaining regulatory approval for their products and the impact of acquisitions on workforce restructuring.The recent rejection by the FDA of a label expansion for Alnylam Pharmaceuticals' drug Onpattro to treat a rare heart condition has caused disappointment for the company. However, CEO Yvonne Greenstreet has outlined the company's future plans.This rejection sheds light on the challenges faced by drugmakers in gaining approval for their treatments. There is a delicate balance between patients and drugmakers wanting more liberal approval processes, while the medical community aims to ensure that drugs provide significant benefits compared to the risks.The FDA has been working towards bridging this gap through programs like Accelerating Rare Disease Cures (ARC). ARC aims to provide education campaigns and resources for developers to ensure all stakeholders are aligned.Alnylam's rejection serves as a reminder that surprises can still arise in the drug development and regulatory arenas. It also highlights the need for continuous innovation and adaptation in this field.Looking ahead, gene editing technology, particularly CRISPR-based therapies, holds great promise and could soon receive US approval. Many startups and scientists are actively working on advancements in this gene editing revolution.In summary, Alnylam's disap

Reading Kenny's website www.bluerockvineyard.com, you will learn that the night he met his wife it was love ar first sight...for him. Tongue tied the rest of the night, the story ends well with solid marriage; lets face it, it would have to be if she stuck around through the creation of a winery. The story behind Blue Rock winery is storied. You gon't just buy a delapidated farmhouse with a collapsed roof on land that many might have said will never work..but sometimes ignorance is bliss and the Kahn's bought it regardless. You might think that Kenny and his wife were Californians who had anticipated this lifestyle all along, no, they are from memphis (the hot bed of the American wine trade) and knew little more that barbecue...but had a hankering of fine food. Have a listen and you too will be mesmorized and inspired by the story.    

#CAMESHIAIREVIEWS From Youtube live --- Send in a voice message: https://podcasters.spotify.com/pod/show/cameshiareviews/message

In which we go to Bafsk, because we hear they're building something terrible there.Theme music by KNIGHT OF THE ROUND - https://knightoftheround.bandcamp.com/You can find Every F'n FF on Twitter, Instagram, or join our Discord!

Bin Lu has been the executive chef of The Restaurant at Blue Rock in Washington, Va., about a two-hour drive from Washington, D.C., in the bucolic Virginia countryside, since it opened in October of 2021. A year-and-a-half in he continues to delight guests with a constantly evolving prix-fixe menu.Lu was born in Shanghai, China, but immigrated to the United States when he was 2 or 3 years old. He was drawn to cooking in college, where he didn't particularly care for the food that was available on campus and figured he could do better on his own. However, he didn't know anything about cooking, and this was long before any recipe or technique could be looked up online. But he did research and got the hang of it and realized that he was spending a lot more time learning to cook than paying attention to school. So upon graduation he started working at restaurants, including CityZen in D.C., under executive chef Eric Ziebold, and at Pineapple and Pearls, also in D.C., where he worked his way up the ranks and ended up as executive chef.He recently shared his approach to cooking and his experimentation in bringing out different flavors in his dishes.

Market fundamentals, earnings, and valuations do not appear to support recovery to previous highs, notes Jeff Schwaber CEO of Bluerock Capital Markets. He talks about how markets are choppy in a back-and-forth session. He mentions that fixed income and credit appear attractive without substantial loss from future rate hikes. He highlights that institutional private real estate positioning for a likely move-up in post-inflationary and rate-hike cycle. He examines market volatility trends, as well as investing alternative assets. He then goes over the Bluerock Total Income+ Real Estate Fund and opportunities in real estate. Tune in to find out more about the stock market today.

Xero have announced that they have decided to retire WorkflowMax (WFM) on 26 June 2024. This episode includes an interview with Cassandra Scott Queen of WorkFlowMax, moderator of the Bookkeepers in Practice Facebook group, and Founder of Laurus Bookkeeping and Matthew Peng Founder of Business Continuum Cloud Integrators and Independant Solution Advisors, sharing their perspectives on the sunsetting of WFM, and recommendations for next steps. A little trip down history lane. WorkFlowMax is a project management software that was founded in 2007 by Chris Spence and Gavin George, initially developed as a job management solution for Steelcraft Engineering business owned by Gavin's brothers. Over the years, WorkFlowMax has become a reliable project management platform utilised by businesses worldwide. In May 2012, Xero, a global accounting software provider, acquired WorkFlowMax, leading to further development and growth of the software. After almost 11 years of servicing clients, Xero recently announced that they will retire WorkFlowMax on June 26, 2024. Three takes on the same story WORKFLOWMAX BLOG https://www.workflowmax.com/blog/future-plans-for-workflowmax? XERO DEVELOPER BLOG https://devblog.xero.com/xero-to-retire-workflowmax-mid-2024-6f12f45e4be XERO BLOG https://www.xero.com/blog/2023/03/xero-announces-future-plans-workflowmax/ It's essential to note that WorkFlowMax is a completely separate solution from Xero Practice Manager (XPM). Therefore, Xero Practice Manager and Xero Tax will not be affected by this decision. Data separation is also guaranteed to ensure the privacy and security of user information. Read more about that here. If you or your clients are impacted by this announcement, here are some options I'm aware of, and please share others that you may know of with me. BlueRock have acquired the “WorkflowMax brand” WorkGuru.io MinuteDock G-Accon Ascora ProjectWorks.io Accelo Scoro StreamTime  

Today I am joined by Peter Lalor, the CEO and Managing Director of Blue Rock - Xero Platinum Partner, and Cloud Integrator. Peter is an experienced Director with a demonstrated history of working with entrepreneurial business owners. With a passion for technology and thinking differently, he's a Chartered Accountant and has started and scaled multiple businesses.  Blue Rock describes itself as ‘We're more than an entrepreneurial advisory firm helping businesses grow and succeed - we're a community.'  In this episode we cover

Primary source alert! Fraggle Rock writer Sugith Varughese joins the boys to talk about what it was like to work on the show. Then, we head back down to Fraggle Rock to cover 4 more episodes. Buckle up, you're going to be riding with Matt and Sam for a while this week! Lucky! Episodes covered: 'Gobo's Discovery,' 'Mokey's Funeral,' 'The Beast of Bluerock,' 'New Trash Heap in Town' Kermitment has a Patreon! Running a podcast is deceptively expensive work, so by becoming our Patron, you help us cover those costs and allow us to do funner, cooler stuff in the future! Find out more here! Visit our website to find a link to the Kermitment Patreon, logo pin and more fun stuff at http://Kermitment.com! If you can't get enough Kermitment, follow @KermitmentPod, where we'll tweet fun stuff and interact with our listeners! And you can follow each of us individually: Matt: @MatthewGaydos Sam: @im_sam_schultz

On this episode of The Final Cast, Matt and Brad are joined by Blue Rock Custom Tackle Owner Jesse French. The guys talk about what makes custom baits so unique and why people should buy into the custom bait market. Jesse explains in detail a few of his best selling baits that he makes here in Ohio. Thanks for tuning in. https://bluerocktackle.com https://instagram.com/bluerockcustomtackle?igshid=NzAzN2Q1NTE= https://www.facebook.com/bluerockcustomtackle?mibextid=LQQJ4d DarkHorse Tackle use promo code PADDLE20 to save 20% off your first monthly subscription here: https://www.darkhorsetackle.com Nikko baits: https://nikko-fishing.com/catalog/ Sign Up For Dale Hollow Event- https://tourneyx.com/leaderboard/standings/paddlenfin-open-at-dale-hollow-2023 Dale Hollow Lodging- www.eastport.info Waypoint TV- https://waypointtv.com Podcast & Website- www.paddlenfin.com YouTube- https://www.youtube.com/paddlenfin Email- paddlenfin@gmail.com Social Media- @paddlenfin Yak Gadget- www.yakgadget.com Pelican Professional- www.pelican.com Rocktown paddlesports - rocktownadventures.com JigMasters Jigs- https://jigmasters.com Learn more about your ad choices. Visit megaphone.fm/adchoices

The average new home today costs somewhere between $200,000 and $400,000 to build. What if there was a better way...? What if you could build your house out of materials that people were throwing away? Free materials, and a building method that was DIY friendly... This is exactly why Annie and Jay built themselves an Earthship. What is an Earthship? An Earthship is a type of sustainable, passive solar home that is made of natural and recycled materials. The design emphasizes self-sufficiency, energy efficiency, and the use of renewable resources... Like beer cans, or in Annie and Jay's case... Tires! Read the Blog Recap HERE Checkout Their Youtube channel Blue Rock Station Website Their Podcast Pioneer Version of this Podcast Become a Pioneer HERE Learn more about your ad choices. Visit megaphone.fm/adchoices

Ramin Kamfar, founder and CEO of Bluerock, joins the program to discuss a host of topics, such as: The main headwind facing real estate investors, as well as the prime tailwind. The most likely property-type-of-the year. What might be the sleeper property type for 2023. The future of office. The U.S. housing crisis. It's all here — those topics and more. (02/2023)

Ramin Kamfar, founder and CEO of Bluerock, joins the program to discuss a host of topics, such as: The main headwind facing real estate investors, as well as the prime tailwind. The most likely property-type-of-the year. What might be the sleeper property type for 2023. The future of office. The U.S. housing crisis. It's all here — those topics and more. (02/2023)

Ramin Kamfar, founder and CEO of Bluerock, joins the program to discuss a host of topics, such as: The main headwind facing real estate investors, as well as the prime tailwind. The most likely property-type-of-the year. What might be the sleeper property type for 2023. The future of office. The U.S. housing crisis. It's all here — those topics and more. (02/2023)

Don't cross him, don't boss him! We're screaming like a panther in the middle of the night this week with Willie Nelson's career-defining classic, Red Headed Stranger! This 1975 concept LP was mistaken for a demo when record execs first heard it, but hits like Blue Eyes Crying In The Rain and Remember Me helped cement its legacy. We'll follow the Preacher on a redemptive journey full of love, lust, and murder, all the way from Blue Rock to Denver. We'll also talk about Willie's hitchhiker lifestyle, his creative use of a barf bag, and the time he was accused of murder as we sail O'er The Waves on Spin It! Keep Spinning at www.SpinItPod.com!Thanks for listening! Hosted on Acast. See acast.com/privacy for more information.

BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson's Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.

Based in Melbourne, where he is the founding director of BlueRock - a multidisciplinary, entrepreneurial advisory firm - Pete Lalor applies his passion for automation and innovation to do things differently. Overseeing 13 service divisions in this company alone, Pete is also a Chairman of the 100 Burgers and Mr Burger groups, a director of Belles Hot Chicken and beyond hospitality, is heavily involved in the property industry and the founder of Rosewood - an early-stage venture capital fund.

Take 1 Let's do this... Finally decided to host a podcast. If you're ready, I'm ready. Show your support and I'll be there for you too. Follow, download and visit my site for other great shows, ~Connie https://www.ConnieWillis.com

Hello again Fellow Golfists, Just wanted to share my most recent golf outing at Blue Rock Springs Golf Course in Vallejo California.  I got to play the West Course recently.  I chatted about my most recent golf round, who I played with, how long it took, funny things that happened, playing in older style golf shoes, new but older clubs I picked up, dealing with a herniated putter, my new handicap index,  trying to putt with a spanish accent, with a flourish of cooler San Pablo bay breeze to finish the round with.   Hoping your next putt is so easy to get in and out of, you know.  Thanks for listening to The Knackered Golfist Podcast   

Four Alumni of this legendary corps talk about its history and the famous “Baby Elephant Walk.”

PRL 6 - 14 - 22 Ellerbe, Billy Weaver, Bryce Williams, Blue Rock report by Pirate Radio

Welcome back and happy Friday Dark Horse Nation! Today we have one of our favorite local bait makers on! Jesse French from Blue Rock Custom Tackle. He is a man with immense knowledge and makes one heck of a jig! If you want to check out his products please check out his social media and website! ***ALSO use code DARKHORSE10 to save a bit of money on his website!*** https://bluerocktackle.com/ https://www.instagram.com/bluerockcustomtackle/ https://www.facebook.com/bluerockcustomtackle See you Monday, have a good weekend!

Blackrock acquisition of BlueRock Residential Growth REIT and (BHOM) Spin-Off.